视觉障碍

互动

阅读原始引用

我们积极参与有关将疗法纳入SUS（Sistema Único de Saúde——统一卫生系统）以及获取高价药品的讨论。

Atuação em debates sobre incorporação de terapias no SUS, acesso a medicamentos de alto custo, participação em discussões sobre ATS e judicialização em doenças raras.

互动

阅读原始引用

我们经常倡导新药上市获批、将视力保健产品纳入省级医疗保险范围，我们的会员也参与CDA（加拿大药品局）的调查和会议。

We often advocate for the acceptance of new drugs to market, the inclusion of vision care products to provincial health coverages, and our members take part in CDA surveys and sessions often.

行动与倡导

阅读原始引用

当加拿大药品局（CDA）决定是否建议公共报销新药时，我们会提供患者意见。我们也向各省提供意见。

We provide patient input to Canada's Drug Agency when they are deciding whether or not to recommend public reimbursement for new drugs. We also provide input to provinces. In the past, we have also advocated directly with the pCPA, which negotiates drug prices, but this is not a regular occurrence.

行动与倡导

阅读原始引用

跨党派议会小组 — IVT [玻璃体腔内治疗] 技术工作组。白内障技术工作组 — 区域合作伙伴关系 — 地方活动。

Gruppo Interparlamentare - Tavolo Tecnico IVT. Tavolo Tecnico Cataratta - Partnership Regionali - Attività Locali.